About Lucier Pharmaceuticals

To address unmet medical needs, Lucier Pharmaceuticals is developing novel drugs toward effectively managing microvascular diseases.

Our drug candidates are based on novel scientifc findings from Texas A&M University, which support one patent (US2024/029067) application.

Pipeline

Preclincial development

LU-1001: injectable small molecular inhibitor to improve the diagnosis of coroanry microvascular dysfunction/disease (CMD).

LU-1002: oral small molecular inhibitor for treating microvascular diseases.

Meet Our Team

Guangrong Lu, MBBS.

Co-inventor

Founder, President and CEO

Lih Kuo, PhD.

Co-inventor

Regents Professor, Scientific Advisor

E.L. Berryman

Reg. Toxicologist

Pre-clinical Development Advisor

Lee Schalop, MD.

Angel Investor and Entrepreneur

Business Advisor